Sebastian Kufner

List of Publications by Year
in descending order

55	2,006	471509 17	243625 44
papers	citations	h-index	g-index

58	58	58	2685
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Longâ€term clinical outcomes after drug eluting stent implantation with and without stent overlap. Catheterization and Cardiovascular Interventions, 2022, 99, 541-551.	1.7	5
2	A prospective trial of a novel <scp>lowâ€dose paclitaxelâ€coated</scp> balloon therapy in patients with restenosis in <scp>drugâ€eluting</scp> coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent <scp>Inâ€stent</scp> REstenosis <scp>3A</scp> (ISARâ€DESIRE 3A). Catheterization and Cardiovascular Interventions, 2022, 99, 754-762.	1.7	2
3	Target and non-target vessel related events at 10 years post percutaneous coronary intervention. Clinical Research in Cardiology, 2022, 111, 787-794.	3.3	6
4	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	5
5	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, e023493.	3.7	5
6	Ten-Year Clinical Outcomes in Patients With Acute Coronary Syndrome Treated With Biodegradable, Permanent-Polymer or Polymer-Free Drug-Eluting Stents.. Journal of Invasive Cardiology, 2022, 34, E266-E273.	0.4	0
7	Diabetes mellitus and femoropopliteal in-stent restenosis. Vasa - European Journal of Vascular Medicine, 2022, , .	1.4	1
8	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e018304.	3.7	9
9	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1121.	6.1	11
10	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. Clinical Research in Cardiology, 2021, 110, 1586-1598.	3.3	7
11	Tenâ€Year Clinical Outcomes of Biodegradable Versus Durable Polymer Newâ€Generation Drugâ€Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	3.7	5
12	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. Clinica Chimica Acta, 2021, 523, 106-113.	1.1	9
13	Procedural and clinical performance of dualâ€versus singleâ€catheter strategy for transradial coronary angiography: A metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, 276-282.	1.7	2
14	Efficacy of drugâ€coated balloon angioplasty in early versus late occurring drugâ€eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. Catheterization and Cardiovascular Interventions, 2020, 96, 1008-1015.	1.7	4
15	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. JACC: Cardiovascular Interventions, 2020, 13, 2266-2274.	2.9	13
16	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. Journal of the American College of Cardiology, 2020, 76, 146-158.	2.8	49
17	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest â€“ A propensity score-matched analysis. PLoS ONE, 2020, 15, e0218634.	2.5	7
18	Sex differences in the outcome after percutaneous coronary intervention â€“ A propensity matching analysis. Cardiovascular Revascularization Medicine, 2019, 20, 101-107.	0.8	17

#	Article	IF	Citations
19	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	27.0	543
20	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. Heart and Vessels, 2019, 34, 1104-1112.	1.2	3
21	Relationship of left ventricular endâ€diastolic pressure with extent of myocardial ischemia, myocardial salvage and longâ€term outcome in patients with STâ€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2019, 93, 901-909.	1.7	8
22	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Circulation, 2019, 139, 325-333.	1.6	97
23	Outcome after new generation singleâ€layer polytetrafluoroethyleneâ€covered stent implantation for the treatment of coronary artery perforation. Catheterization and Cardiovascular Interventions, 2019, 93, 912-920.	1.7	22
24	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2019, 123, 199-205.	1.6	9
25	What Treatment Should We Dare in Patients With In-Stent Restenosis?. JACC: Cardiovascular Interventions, 2018, 11, 284-286.	2.9	4
26	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. Journal of Cardiology, 2018, 72, 220-226.	1.9	15
27	Comparative prognostic value of postprocedural creatine kinase myocardial band and highâ€sensitivity troponin T in patients with nonâ€STâ€segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 91, 215-223.	1.7	16
28	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. International Journal of Cardiology, 2018, 252, 57-62.	1.7	16
29	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e006752.	3.9	32
30	ISARâ€PEBIS (Paclitaxelâ€Eluting Balloon Versus Conventional Balloon Angioplasty for Inâ€Stent Restenosis) Tj ETQq0 0 0 rgBT /Overloc	3.7	38
31	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2017, 10, 1332-1340.	2.9	98
32	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. EuroIntervention, 2017, 13, 962-969.	3.2	6
33	Diagnosis and management of intramyocardial hematoma after coronary artery perforation. Coronary Artery Disease, 2016, 27, 327-330.	0.7	1
34	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. Clinical Biochemistry, 2016, 49, 1127-1132.	1.9	8
35	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clinical Research in Cardiology, 2016, 105, 575-584.	3.3	18
36	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Cardiovascular Diabetology, 2016, 15, 124.	6.8	13

#	Article	IF	Citations
37	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 2259-2268.	2.8	88
38	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting StentsÂVersus Durable Polymer Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 784-792.	2.9	52
39	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	3.2	60
40	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 877-884.	2.9	85
41	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. Cardiovascular Revascularization Medicine, 2015, 16, 156-162.	0.8	26
42	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	2.7	9
43	Drug-eluting stents for drug-eluting stent restenosis. Coronary Artery Disease, 2014, 25, 633-635.	0.7	0
44	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. Cardiovascular Revascularization Medicine, 2014, 15, 69-75.	0.8	12
45	Secondâ€versus firstâ€generation â€œLimusâ€â€eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISARâ€TESTâ€4 trial. Catheterization and Cardiovascular Interventions, 2013, 82, E769-76.	1.7	13
46	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiology Journal, 2012, 19, 61-69.	1.2	19
47	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. American Heart Journal, 2011, 162, 740-747.	2.7	24
48	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. Clinical Research in Cardiology, 2011, 100, 561-570.	3.3	38
49	Fiveâ€year clinical outcomes of sirolimusâ€eluting versus paclitaxelâ€eluting stents in highâ€risk patients. Catheterization and Cardiovascular Interventions, 2011, 77, 494-501.	1.7	17
50	Angiographic outcomes with biodegradable polymer and permanent polymer drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2011, 78, 161-166.	1.7	13
51	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. EuroIntervention, 2011, 7, 128-135.	3.2	8
52	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2710-2716.	2.8	192
53	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2010, 63, 770-778.	0.6	7
54	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. European Heart Journal, 2009, 30, 2441-2449.	2.2	207

#	Article	IF	Citations
55	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. JACC: Cardiovascular Interventions, 2009, 2, 1142-1148.	2.9	20